Novel variations and loss of heterozygosity of BRCA2 identified in a dog with mammary tumors

American Journal of Veterinary Research

Volumn 69, Issue 10, 2008, Pages 1323-1328

  Yoshikawa, Yasunaga ^a   Morimatsu, Masami ^b   Ochiai, Kazuhiko ^c   Nagano, Masashi ^d   Tomioka, Yukiko ^b   Sasaki, Nobuo ^e   Hashizume, Kazuyoshi ^f   Iwanaga, Toshihiko ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

^d TOTTORI UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f IWATE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BREAST TUMOR; CONTROLLED STUDY; DNA DETERMINATION; DOG DISEASE; GENE EXPRESSION; GENE INSERTION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; MICROSATELLITE MARKER; MISSENSE MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BASE SEQUENCE; BRCA2 PROTEIN; CLONING, MOLECULAR; DNA PRIMERS; DNA, COMPLEMENTARY; DNA, NEOPLASM; DOG DISEASES; DOGS; FEMALE; LOSS OF HETEROZYGOSITY; MAMMARY NEOPLASMS, ANIMAL; OPEN READING FRAMES; VARIATION (GENETICS);

CANIS FAMILIARIS;

EID: 56049103795     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.69.10.1323     Document Type: Article

References (43)

1. Sorenmo K. Canine mammary gland tumors. Vet Clin North Am Small Anim Pract 2003;33:573-596.
2. Priester WA, Mantel N. Occurrence of tumors in domestic animals. Data from 12 United States and Canadian colleges of veterinary medicine. J Natl Cancer Inst 1971;47:1333-1344.
3. Dorn CR, Taylor DO, Schneider R, et al. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst 1968;40:307-318.
4. Moe L. Population-based incidence of mammary tumours in some dog breeds. J Reprod Fertil Suppl 2001;57:439-443.
5. Fidler IJ, Brodey RS. The biological behavior of canine mammary neoplasms. J Am Vet Med Assoc 1967;151:1311-1318.
6. Hamilton JM. Comparative aspects of mammary tumors. Adv Cancer Res 1974;19:1-45.
7. Priester WA. Occurrence of mammary neoplasms in bitches in relation to breed, age, tumour type, and geographical region from which reported. J Small Anim Pract 1979;20:1-11.
8. Davies AA, Masson JY, McIlwraith MJ, et al. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 2001;7:273-282.
9. Pellegrini L, Yu DS, Lo T, et al. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 2002;420:287-293.
10. Yu DS, Sonoda E, Takeda S, et al. Dynamic control of Rad51 recombinase by self-association and interaction with BRCA2. Mol Cell 2003;12:1029-1041.
11. Sharan SK, Morimatsu M, Albrecht U, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997;386:804-810.
12. Chen PL, Chen CF, Chen Y, et al. The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci U S A 1998;95:5287-5292.
13. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171-182.
14. Esashi F, Christ N, Gannon J, et al. CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature 2005;434:598-604.
15. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002;297:606-609.
16. Taniguchi T, D'Andrea AD. Molecular pathogenesis of Fanconi anemia: recent progress. Blood 2006;107:4223-4233.
17. Reid S, Schindler D, Hanenberg H, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 2007;39:162-164.
18. Xia B, Dorsman JC, Ameziane N, et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 2007;39:159-161.
19. Hussain S, Witt E, Huber PA, et al. Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1. Hum Mol Genet 2003;12:2503-2510.
20. Hussain S, Wilson JB, Medhurst AL, et al. Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. Hum Mol Genet 2004;13:1241-1248.
21. Wang X, Andreassen PR, D'Andrea AD. Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol Cell Biol 2004;24:5850-5862.
22. Hussain S, Wilson JB, Blom E, et al. Tetratricopeptide-motif-mediated interaction of FANCG with recombination proteins XRCC3 and BRCA2. DNA Repair (Amst) 2006;5:629-640.
23. Xia B, Sheng Q, Nakanishi K, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 2066;22:719-729.
24. Godthelp BC, Wiegant WW, Waisfisz Q, et al. Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2. Mutat Res 2006;594:39-48.
25. Ohashi A, Zdzienicka MZ, Chen J, et al. Fanconi anemia complementation group D2 (FANCD2) functions independently of BRCA2- and RAD51-associated homologous recombination in response to DNA damage. J Biol Chem 2005;280:14877-14883.
26. Milner J, Ponder B, Hughes-Davies L, et al. Transcriptional activation functions in BRCA2. Nature 1997;386:772-773.
27. Fuks F, Milner J, Kouzarides T. BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene 1998;17:2531-2534.
28. Siddique H, Zou JP, Rao VN, et al. The BRCA2 is a histone acetyltransferase. Oncogene 1998;16:2283-2285.
29. Shin S, Verma IM. BRCA2 cooperates with histone acetyltransferases in androgen receptor-mediated transcription. Proc Natl Acad Sci U S A 2003;100:7201-7206.
30. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003;348:2339-2347.
31. Cleton-Jansen AM, Collins N, Lakhani SR, et al. Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13. Br J Cancer 1995;72:1241-1244.
32. Collins N, McManus R, Wooster R, et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 1995;10:1673-1675.
33. Gudmundsson J, Johannesdottir G, Bergthorsson JT, et al. Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. Cancer Res 1995;55:4830-4832.
34. Lancaster JM, Wooster R, Mangion J, et al. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 1996;13:238-240.
35. Osorio A, de la Hoya M, Rodríguez-López R, et al. Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer. Int J Cancer 2002;99:305-309.
36. Yoshikawa Y, Morimatsu M, Ochiai K, et al. Analysis of genetic variations in the exon 27 region of the canine BRCA2 locus. J Vet Med Sci 2005;67:1013-1017.
37. Vassetzky NS, Kramerov DA. CAN - a pan-carnivore SINE family. Mamm Genome 2002;13:50-57.
38. Yoshikawa Y, Morimatsu M, Ochiai K, et al. Insertion/deletion polymorphism in the BRCA2 nuclear localization signal. Biomed Res 2005;26:109-116.
39. Ghebranious N, Donehower LA. Mouse models in tumor suppression. Oncogene 1998;17:3385-3400.
40. Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci U S A 1993;90:10914-10921.
41. Wong AK, Pero R, Ormonde PA, et al. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem 1997;272:31941-31944.
42. Ochiai K, Morimatsu M, Yoshikawa Y, et al. Brca2 C-terminus interacts with Rad51 and contributes to nuclear focus formation in double-strand break repair of DNA. Biomed Res 2004;25:269-275.
43. National Human genome Research Institute Web site. The breast cancer information core database. Available at: http://research.nhgri.nih.gov/ projects/bic/Member/index.shtml. Accessed Feb 28,2007.